Infertility is no longer a silent struggle. As more individuals and couples seek help to start or expand their families, assisted reproductive technologies (ART) are becoming central to modern healthcare. What was once considered taboo or out of reach is a rapidly growing global industry backed by science, shifting cultural norms, and medical innovation.
From in vitro fertilization (IVF) to egg freezing, sperm donation, and surrogacy, ART procedures are offering new hope, and driving one of the most dynamic markets in healthcare.
According to market research, the global market for assisted reproductive technologies was valued at an estimated $35.4 billion in 2024 and is slated to reach $53.8 billion by the end of 2030.
Assisted Reproductive Technologies refers to medical procedures used primarily to address infertility. They involve the handling of eggs, sperm, or embryos to achieve pregnancy. The most common forms of ART include:
ART is more than just a fertility service, it’s a lifeline for millions. It helps same-sex couples, single parents, cancer survivors, and people with medical conditions preserve and exercise their reproductive rights.
The global market for assisted reproductive technologies is witnessing significant and sustained growth. Factors contributing to this rise include:
As awareness grows and stigma fades, clinics and fertility centers worldwide are experiencing higher patient volumes. This demand also drives innovation in AI-assisted embryo selection, non-invasive diagnostics, and cryopreservation technologies.